Tradestie Institutional Equity Comparison Engine
LMRI vs LBRX โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
LBRX Overall Edge
LBRX Captures Institutional Edge (3โ0 Pillars ยท 8โ0 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to LB Pharmaceuticals Inc Common Stock (LBRX) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, LMRI trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus LBRX at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, LMRI sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against LBRX sits in CONSOLIDATION (4th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
LMRI N/M vs LBRX N/M Fwd P/E
Growth & Margin Winner
LBRX
Op Margin N/A vs 0.0% ยท YoY N/A vs +0.0%
Momentum & Technical Winner
LBRX
1Y -23.0% vs +144.7% ยท 52W Pos 60% vs 68%
Options & Structure Winner
LBRX
UNCLASSIFIED (N/A IV) vs CONSOLIDATION (4th %ile IV)
LMRI
US Equity
LMRI
Institutional Equity
$14.26
+1.42% 1D
Market Cap
N/A
1M Return
+30.95%
1Y Return
-23.0%
Forward P/E
N/M
Unified AI Score
32.1 / 100
SELL
Tech 50.0
Fund 30.0
Flow 50.0
Mom 50.0
LBRX
NASDAQ
LB Pharmaceuticals Inc Common Stock
Pharmaceutical Preparations
$38.85
-2.97% 1D
Market Cap
$1.3B
1M Return
-1.45%
1Y Return
+144.72%
Forward P/E
N/M
Unified AI Score
38.2 / 100
SELL
Tech 20.0
Fund 36.0
Flow 54.0
Mom 40.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
LMRI -23.0%
LBRX +144.72%
Spread: +115.04 pp (LBRX Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
LMRI TTM Op. Margin: N/A
LBRX TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on LMRI vs LBRX. Trailing 12-month operating profitability (LMRI N/A vs LBRX 0.0%) and valuation multiples (LMRI N/M vs LBRX N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | LMRI | LBRX | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | N/A | $1.3B | Larger Scale | LBRX |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | N/A | +0.0% | Higher Growth | LBRX |
| Operating Margin (TTM) Profitability | N/A | 0.0% | Higher Margin | LBRX |
| Net Profit Margin Profitability | N/A | 0.0% | Higher Margin | LBRX |
| Return on Equity (ROE) Capital Efficiency | N/A | -38.8% | Higher ROE | LBRX |
| 52-Week Range Position Momentum | 60% ($6โ$19) | 68% ($15โ$50) | Stronger Trend | LBRX |
| Beta / 30D Volatility Risk Regime | 1.22ฮฒ ยท 85% Vol | 1.07ฮฒ ยท 60% Vol | Lower Realized Risk | LBRX |
| Unified Institutional Score Composite Signal | 32.1 / 100 (SELL) | 38.2 / 100 (SELL) | Higher Composite | LBRX |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full LMRI vs LBRX Buy Guide
LMRI
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
LBRX
CONSOLIDATION
66d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
4th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither LMRI nor LBRX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.